Updated: Cellares to produce Cabaletta’s autoimmune CAR-T candidate
Cellares announced a new proof-of-concept partnership with Cabaletta Bio to manufacture the biotech’s autoimmune CAR-T cell therapy.
The goal of the program is to “test the Cellares system using Cabaletta’s process and product to assess the platform’s ability to manufacture CABA-201,” Cabaletta’s CD19-CAR T candidate, according to Cabaletta chief business officer Arun Das. The trials are evaluating multiple indications: systemic lupus erythematosus, myositis, systemic sclerosis and generalized myasthenia gravis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.